TransEnterix Inc., a company that manufactures robots that can perform medical surgeries, announced Tuesday that it received U.S. Food and Drug Administration clearance for its Senhance Ultrasonic System.

The Senhance system is a multi-port system that brings the advantages of robotic surgery to patients and is the first new abdominal robotic surgery platform to receive FDA clearance since 2000.

“Advanced energy devices are used within a high percentage of cases across a wide range of procedures, which make them a critical tool for laparoscopic surgeons,” said CEO Todd M. Pope in a statement. “We believe the addition of the Senhance Ultrasonic System is significant and broadens the attractiveness of the Senhance platform and digital laparoscopy for surgeons in the U.S.”

Advanced energy devices are becoming more popular around the country and are improving the patient and surgeon experience for all.

“The addition of ultrasonic technology is a significant expansion of the Senhance system capability preferred by many surgeons during complex procedures,” said Dr. Steven D. McCarus, chief of gynecologic surgery at Florida Hospital Celebration Health.

Founded in 2006, TransEnterix creates advanced technologies to perform minimally invasive surgeries. In the United States, the Senhance system is now approved for laparoscopic colorectal, gynecological, inguinal hernia and gallbladder removal surgery.

The company’s stock closed Tuesday at $2.66, unchanged.